tetano
Editor, Senior Moderator
Sci Rep. 2017 Sep 26;7(1):12336. doi: 10.1038/s41598-017-12101-3.
[h=1]Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains.[/h] Hsu KC[SUP]1[/SUP], Hung HC[SUP]2[/SUP], HuangFu WC[SUP]1[/SUP], Sung TY[SUP]3[/SUP], Eight Lin T[SUP]1[/SUP], Fang MY[SUP]2[/SUP], Chen IJ[SUP]2[/SUP], Pathak N[SUP]4[/SUP], Hsu JT[SUP]5,[/SUP][SUP]6[/SUP], Yang JM[SUP]7,[/SUP][SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is an annual seasonal epidemic that has continually drawn public attentions, due to the potential death toll and drug resistance. Neuraminidase, which is essential for the spread of influenza virus, has been regarded as a valid target for the treatment of influenza infection. Although neuraminidase drugs have been developed, they are susceptible to drug-resistant mutations in the sialic-binding site. In this study, we established computational models (site-moiety maps) of H1N1 and H5N1 to determine properties of the 150-cavity, which is adjacent to the drug-binding site. The models reveal that hydrogen-bonding interactions with residues R118, D151, and R156 and van der Waals interactions with residues Q136, D151, and T439 are important for identifying 150-cavitiy inhibitors. Based on the models, we discovered three new inhibitors with IC[SUB]50[/SUB] values <10 μM that occupies both the 150-cavity and sialic sites. The experimental results identified inhibitors with similar activities against both wild-type and dual H274Y/I222R mutant neuraminidases and showed little cytotoxic effects. Furthermore, we identified three new inhibitors situated at the sialic-binding site with inhibitory effects for normal neuraminidase, but lowered effects for mutant strains. The results suggest that the new inhibitors can be used as a starting point to combat drug-resistant strains.
PMID: 28951584 DOI: 10.1038/s41598-017-12101-3
Free full text
[h=1]Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains.[/h] Hsu KC[SUP]1[/SUP], Hung HC[SUP]2[/SUP], HuangFu WC[SUP]1[/SUP], Sung TY[SUP]3[/SUP], Eight Lin T[SUP]1[/SUP], Fang MY[SUP]2[/SUP], Chen IJ[SUP]2[/SUP], Pathak N[SUP]4[/SUP], Hsu JT[SUP]5,[/SUP][SUP]6[/SUP], Yang JM[SUP]7,[/SUP][SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza is an annual seasonal epidemic that has continually drawn public attentions, due to the potential death toll and drug resistance. Neuraminidase, which is essential for the spread of influenza virus, has been regarded as a valid target for the treatment of influenza infection. Although neuraminidase drugs have been developed, they are susceptible to drug-resistant mutations in the sialic-binding site. In this study, we established computational models (site-moiety maps) of H1N1 and H5N1 to determine properties of the 150-cavity, which is adjacent to the drug-binding site. The models reveal that hydrogen-bonding interactions with residues R118, D151, and R156 and van der Waals interactions with residues Q136, D151, and T439 are important for identifying 150-cavitiy inhibitors. Based on the models, we discovered three new inhibitors with IC[SUB]50[/SUB] values <10 μM that occupies both the 150-cavity and sialic sites. The experimental results identified inhibitors with similar activities against both wild-type and dual H274Y/I222R mutant neuraminidases and showed little cytotoxic effects. Furthermore, we identified three new inhibitors situated at the sialic-binding site with inhibitory effects for normal neuraminidase, but lowered effects for mutant strains. The results suggest that the new inhibitors can be used as a starting point to combat drug-resistant strains.
PMID: 28951584 DOI: 10.1038/s41598-017-12101-3
Free full text